The p38 MAPK pathway mediates both antiinflammatory and proinflammatory processes: Comment on the article by Damjanov and the editorial by Genovese

Arthritis and Rheumatism

Volumn 60, Issue 11, 2009, Pages 3513-3514

  Clark, Andrew R ^a   Dean, Jonathan L E ^a   Saklatvala, Jeremy ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; INFLAMMATION; LETTER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1; MAP KINASE KINASE 4; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70350537135     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24919     Document Type: Letter

References (11)

1. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009;60:1232-1241
2. Genovese MC. Inhibition of p38: has the fat lady sung? [editorial]. Arthritis Rheum 2009;60:317-320
3. Carrick DM, Lai WS, Blackshear PJ. The tandem CCCH zinc finger protein tristetraprolin and its relevance to cytokine mRNA turnover and arthritis. Arthritis Res Ther 2004;6:248-264
4. Koprak S, Staruch MJ, Dumont FJ. A specific inhibitor of the p38 mitogen activated protein kinase affects differentially the production of various cytokines by activated human T cells: dependence on CD28 signaling and preferential inhibition of IL-10 production. Cell Immunol 1999;192:87-95. (Pubitemid 29172074)
5. Ananieva O, Darragh J, Johansen C, Carr JM, McIlrath J, Park JM, et al. The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. Nat Immunol 2008;9:1028-1036
6. Brook M, Tchen CR, Santalucia T, McIlrath J, Arthur JS, Saklatvala J, et al. Posttranslational regulation of tristetraprolin subcellular localization and protein stability by p38 mitogen-activated protein kinase and extracellular signal-regulated kinase pathways. Mol Cell Biol 2006;26:2408-2418 (Pubitemid 43346939)
7. Hitti E, Iakovleva T, Brook M, Deppenmeier S, Gruber AD, Radzioch D, et al. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol Cell Biol 2006;26:2399-2407 (Pubitemid 43346938)
8. Breitwieser W, Lyons S, Flenniken AM, Ashton G, Bruder G, Willington M, et al. Feedback regulation of p38 activity via ATF2 is essential for survival of embryonic liver cells. Genes Dev 2007;21:2069-2082 (Pubitemid 47267292)
9. Hu JH, Chen T, Zhuang ZH, Kong L, Yu MC, Liu Y, et al. Feedback control of MKP-1 expression by p38. Cell Signal 2007;19:393-400. (Pubitemid 46017084)
10. Abraham SM, Clark AR. Dual-specificity phosphatase 1: a critical regulator of innate immune responses. Biochem Soc Trans 2006;34:1018-1023 (Pubitemid 46768980)
11. Mendoza H, Campbell DG, Burness K, Hastie J, Ronkina N, Shim JH, et al. Roles for TAB1 in regulating the IL-1-dependent phosphorylation of the TAB3 regulatory subunit and activity of the TAK1 complex. Biochem J 2008;409:711-722 (Pubitemid 351214197)